AlphaGen

AlphaGen is a clinical-stage biotechnology company specializing in the discovery and development of next-generation targeted alpha therapies (TAT) for cancer. Headquartered in Singapore and incubated by 6 Dimensions Capital, the company focuses on radiopharmaceuticals that utilize potent alpha-emitting isotopes, such as Actinium-225, to deliver localized radiation directly to tumor cells. Their lead program, AG-001, is a PSMA-targeted radioligand therapy currently being evaluated in clinical trials for the treatment of metastatic castration-resistant prostate cancer. AlphaGen leverages a proprietary technology platform to optimize the pharmacokinetic properties of its candidates, aiming to provide more effective and less toxic alternatives to traditional oncology treatments. The company is strategically positioned to address significant unmet needs in the global radiopharmaceutical market, with a particular focus on the Asia-Pacific region.